Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
- Friday, November 27, 2020, 7:13
- PR Newswire
- Add a comment
CARMIEL, Israel, Nov. 27, 2020 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
About the Author
admin has written 20652 stories on this site.